Labcorp Holdings (LH) is back in focus after announcing an expanded collaboration with Epic, embedding its full diagnostic test menu into Epic's Aura platform to simplify ordering and results for hospitals and health systems.

Recent share price performance has been softer, with the stock down 8.52% on a 3 month share price basis and 3.69% over 1 month. However, the 1 year total shareholder return of 6.10% and 3 year total shareholder return of 41.06% still point to longer term gains.

If this kind of health focused digital rollout interests you, it could be worth scanning for other opportunities in healthcare technology using our screener of 33 healthcare AI stocks

With Labcorp reporting quarterly net income of US$277.8 million, annual revenue of US$14.1b and what appears to be a sizeable gap to some valuation estimates, investors may ask whether there is still upside potential here or whether the market is already pricing in future growth.

Most Popular Narrative: 18% Undervalued

Labcorp's most followed valuation storyline points to a fair value of $310.06 per share, compared with the last close of $254.42. In that framework, the stock is framed as materially underpriced.

The introduction of innovative tests in oncology, women's health, autoimmune disease, and neurology is anticipated to capture more test volume and outpace growth in the broader market, positively impacting revenue and earnings. The use of AI and technology innovations is enhancing operational efficiencies, improving margins through platforms like eClaim Assist and Labcorp Diagnostic Assistant.

Want to see what is baked into that valuation gap? The narrative focuses on expanding test volumes, firmer margins, and a future earnings profile that assumes tighter cost discipline.

Result: Fair Value of $310.06 (UNDERVALUED)

However, that upside story could be challenged if tariffs and regulatory changes squeeze margins, or if tougher competition in diagnostics pressures pricing as contracts renew.

Next Steps

With both risks on the radar and tangible rewards attracting attention, it makes sense to move quickly, review the data yourself, and weigh up the 5 key rewards and 2 important warning signs

Looking for more investment ideas?

If you stop with Labcorp, you could miss other stocks that fit your style, so put the Simply Wall Street Screener to work across different angles.

• Target potential value opportunities by scanning companies that screen well on quality and price using our 47 high quality undervalued stocks.
• Prioritise resilience first by focusing on businesses highlighted in the 68 resilient stocks with low risk scores that score well on lower overall risk.
• Hunt for lesser known opportunities that still have solid fundamentals through the screener containing 23 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.